Agreed. Well run company with a robust pipeline including several potential blockbusters, excellent trial results across the board so far, near term (modest) revenue from NDA-approved product, and a hovering under $200MM market cap. Seems like a very decent long-term investment.
Nice presentation at the showcase today. No surprises, which is good because it means things are on track. The goof up surrounding the start/stop/start offering a couple months back seems to have ended with little damage to price. The company holds 40-50% of its markets cap in cash while in the middle of several late stage trials. I like the chance for a multiple here by the end of 2018.
News 
Market Data 
Discover 
